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PMH4
CLINICAL, HUMANISTIC, AND ECONOMIC 
OUTCOMES ASSOCIATED WITH LONG-TERM 
TREATMENT OF MANIA WITH OLANZAPINE
Namjoshi M, Edgell ET, Feldman PD, Sanger TM, Tohen MF, 
Breier A
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, USA
OBJECTIVE: To determine the clinical, humanistic, and
economic outcomes associated with olanzapine in the
treatment of mania. METHODS: Patients with Bipolar I
Disorder and a confirmed diagnosis of mania were ran-
domized to either olanzapine (5–20mg) or placebo for 3
weeks. The acute phase was followed by a 49-week open
label extension phase in which all patients were treated
with olanzapine. The Young Mania Rating Scale (Y-MRS)
and the Medical Outcomes Study Short Form 36 (SF-36)
were used to assess changes in clinical and humanistic
outcomes, respectively. Health care resource use data
was collected and corresponding costs calculated for the
extension. RESULTS: During the acute phase, the olan-
zapine treatment group experienced a statistically signifi-
cant (P  0.02) mean improvement from baseline in the
YMRS total score compared to placebo. Olanzapine-
treated patients also experienced a statistically significant
(P  .001) mean improvement in clinical symptoms over
the extension. Health-related quality of life improvements
were seen in several dimensions both in the 3-week acute
phase and the extension. Statistically significant differ-
ences in the SF-36 dimensions of bodily pain (P  .001),
general health (P  .009), role emotional (P  .03), and
social functioning (P  .004) were seen in the extension.
In the 52 weeks prior to the study, patients spent an aver-
age of 4.1% of their time hospitalized compared with
only 1.3% of their time during the extension. This reduc-
tion led to a mean total cost savings of almost $900 per
month during the extension compared with the 52 weeks
prior to the study. CONCLUSION: Olanzapine had a posi-
tive impact on the clinical, humanistic, and economic
outcomes in patients with mania, and may be a cost-
effective treatment option in this population.
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IMPACT OF AMISULPRIDE ON HEALTH CARE 
RESOURCES IN SCHIZOPHRENIA: PRELIMINARY 
RESULTS OF A FRENCH STUDY
Levy E1, Olie JP2, Spiesser J3
1University Paris-Dauphine, Paris, France; 2Sainte Anne 
Hospital, Paris, France; 3Health Economics and Outcomes 
Research Department, Sanofi-Synthelabo Corporate, Bagneux, 
France
OBJECTIVES: Describe reasons for and economic conse-
quences of a switch from various antipsychotics to amisul-
pride in 150 schizophrenic patients. METHOD: Multi-
centre in a “real life” setting study over a 2-year period
(Switch  D0;  365 days). Data are collected from hos-
pital records of patients switched from various antipsy-
chotics to amisulpride between January 1997, and Febru-
ary 1999. Change in hospitalization is analyzed using 2
hypothesis, partition at D0, and partition at W6 (hospi-
talizations during the first 6 weeks of amisulpride are at-
tributed to failure of previous treatment and results adjusted
to one year). RESULTS: Socio-demographic characteristics
observed on the first 25 files suggest that the population
of the study does not differ from the general schizo-
phrenic population. Previous treatment (76% classical
antipsychotic, 12% atypical antipsychotic) was stopped
at D0. The reasons for the switch are lack of efficacy
(64%) and side effects (36%). Results show a decrease in
hospitalization after the switch. Partition at D0: 12
days for full time hospitalization, 38 for part time hos-
pitalization, 23 for part time night. Partition at W6: re-
spectively 38, 44 and 23 days. The maximum of
days hospitalized decreases after the switch from 338 to
187 for full time hospitalization, 365 to 208 for part time
day and from 62 to 31 for part time night. Outpatients
are more regularly followed after the switch:4 visits for
patients followed in community, 3 visits for patients
hospitalized at least one time. Initiated dose of amisul-
pride remains the same after one year. CONCLUSION:
Preliminary results show a trend for a decrease in hospi-
talization and an increase in outpatient visits. If this is
confirmed, it would mean that amisulpride is able to cut
the major cost of this disease and to improve the follow-
up of schizophrenic patients in community.
PMH6
ANTIPSYCHOTIC TREATMENT, ADVERSE 
EVENTS AND HEALTH-RELATED QUALITY
OF LIFE
Badia X1, Casado A1, Sacristán JA2, Gómez JC2, Gregor KJ3, 
Gavart S3 and the EFESO Study Group
1Public Health Institute of Catalonia, Barcelona, Spain; 2Clinical 
Research Department, Lilly S.A., Madrid, Spain; 3Eli Lilly and 
Company, Erl Wood, UK
OBJECTIVE: Investigate the relationship between ad-
verse events and health-related quality of life (HRQoL) in
patients receiving antipsychotics for schizophrenia. METH-
ODS: The analyses included a subset of patients from a
large 6-month, prospective, observational study of outpa-
tients receiving antipsychotics for schizophrenia. The
analyses included the most commonly (1%) recorded
adverse events. The HRQoL was evaluated using the EQ-
5D Index (EQ-I) and Visual Analog Scale (VAS). RE-
SULTS: The analyses included 2,128 olanzapine, 417 ris-
peridone, and 112 haloperidol treated patients. The most
common (1%) adverse events were: tremor, hypokine-
sia/akinesia, rigidity, akathesia, dystonia, dyskinesia, weight
gain, and somnolence. Compared to olanzapine-treated
patients, haloperidol-treated patients had significantly
higher incidences for 5 of the extrapyramidal symptoms
and risperidone-treated patients had significantly higher
incidences for 4 of the extrapyramidal symptoms. Ris-
peridone and haloperidol treated patients were signifi-
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cantly more likely than olanzapine-treated patients to ex-
perience multiple extrapyramidal symptoms. Olanzapine
patients were significantly more likely to experience
weight gain compared to risperidone and haloperidol pa-
tients. Regression models indicated that akathisia, hy-
pokinesia/akinesia, and the total number of extrapyrami-
dal symptoms were significantly associated with decreases
in the EQ-I and VAS scores from baseline to the 6-month
end-point. Weight gain and somnolence were not signifi-
cantly associated with EQ-I or VAS score changes from
baseline to the 6-month end-point. CONCLUSIONS:
The results demonstrated an inverse relationship between
adverse events and HRQoL in patients treated with an-
tipsychotics for schizophrenia. Akathisia, hypokinesia/
akinesia, and number of extrapyramidal symptoms had a
significant impact on HRQoL. The relationship between
weight gain or somnolence with HRQoL was not significant.
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TREATMENT PATTERNS OF PATIENTS WITH 
SCHIZOPHRENIA AND SCHIZO-AFFECTIVE 
DISORDER ACROSS 15 COUNTRIES
Patel A, Knapp M, Beecham J
Centre for the Economics of Mental Health, Institute of 
Psychiatry, London, UK
OBJECTIVE: To describe and compare treatment pat-
terns of patients with schizophrenia/schizo-affective dis-
order across 15 different countries. METHODS: Exami-
nation of baseline data from a prospective, multi-centre,
double blind, randomized comparison of quetiapine and
chlorpromazine. 381 patients were recruited from 12 Eu-
ropean countries plus Canada, Australia and South Af-
rica. An economic assessment (Client Services Receipt In-
ventory) included questions about health service use in
the 3 months prior to assessment and was adapted as far
as possible to obtain internationally comparable informa-
tion. Analyses are on country-level data, irrespective of
treatment group. RESULTS: Overall, 62% of patients
had a diagnosis of paranoid schizophrenia. Mean patient
age for each country ranged from 27 to 40 years and the
proportion of males ranged between 0–85%. There were
notable variations in service use. The proportion of pa-
tients in each country who reported using any health ser-
vices ranged between 69–100%. There was a large varia-
tion in the proportions using inpatient services (range
23–100%) and average length of stay (range 7–76 days).
Take-up of community-based services also differed across
countries: 0–75% seeing community psychiatric nurses,
0–46% seeing social workers and 0–75% seeing a gen-
eral practitioner. Graphical representation of treatment
patterns using starplots showed striking similarities be-
tween Australia and the UK; and Canada and Norway.
CONCLUSION: The pre-treatment baseline data are of
interest in their own right as they provide a unique op-
portunity to examine existing treatment patterns across a
large number of countries. Sources of treatment variation
across countries can be numerous and complex, depend-
ing on national, local and patient level factors. Such interna-
tional variations should lead us to question whether results
from a study conducted in one country can easily be used to
inform mental health purchasing decisions in another.
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PHARMACOECONOMIC MODELLING IN 
DEPRESSION: AID OR TRAP
Toumi M, François C, Hansen K
Department of Pharmacoeconomics Lundbeck Laboratories, 
Paris, France
OBJECTIVE: Pharmacoeconomic evaluation of selective
serotonin reuptake inhibitors (SSRIs) is becoming an im-
portant issue for regulatory and marketing purposes. At
the time of the launch of the drug, decision-tree models
(i.e. Markov and Monte-Carlo) provide the most realistic
projection data available. Designed to provide a large
range of information on outcome and cost, which are
based on various assumptions, the models enable deci-
sion-makers (physician, pharmacist, HMO, regulatory
etc.) to make informed, relative decisions. METHODS:
This poster illustrates five different model structures of
associated expenses that are incurred during the treat-
ment of Depression. The branches on these models be-
come progressively complex, and are based on the fol-
lowing five factors: (1) severity of the depression, (2) rate
of compliance, (3) success/failure rate, (4) patient drop-
out from the health care system (patient having no con-
tact with any medical institution or any medical doctor),
and (5) switch in case of failure or non tolerability. Costs
were taken from the literature using different sources.
RESULTS: SSRIs could be more or less cost-effective
than tricyclic antidepressants (TCAs) depending on whether
switch, compliance, success of treatment, dropout from
the health care system and disease have been taken into
consideration. Conversely, when the same information is
derived from different sources of the same country, the
cost-effectiveness ratio is significantly affected. More-
over, sensitivity analysis does not prevent such differ-
ences in outcome. CONCLUSIONS: Caution should be
used when reviewing such data as these results indicate
the tendency for gross discrepancy to exist between dif-
ferent methods of analysis. These results thus emphasize
the need for standardized pharmacoeconomic models.
The authors make arguments in support of this endeavor.
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WITHDRAWN
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SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC 
TREATMENT AND COMPLIANCE
IN SCHIZOPHRENIA
García-Cabeza I1, Gómez JC2, Sacristán JA2, Edgell ET3, 
González de Chavez M1, Gavart S4 and the EFESO Study 
Group
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